UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November ~~August 30~~1, 2011

NOVADEL PHARMA INC.

(Exact Name of Registrant as Specified in Its Charter)


Delaware	001-32177	22-2407152
(State or other jurisdiction of incorporation or organization)	(Commission File No.)	(I.R.S. Employer Identification No.)

1200 Route 22 East, Suite 2000

Bridgewater, NJ 08807

(Address of principal executive offices) (Zip Code)

(908) 203-4640

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 82.0102. Results ~~Other~~of ~~Events~~Operations and Financial Condition.

On November ~~August 30~~1, 2011, NovaDel Pharma Inc., a Delaware corporation, (the “Company”), ~~announced~~issued ~~that~~a ~~the~~press ~~recent~~release ~~decision in the court~~ to ~~uphold~~report ~~Pfizer’s use patent for erectile dysfunction (“ED”) to 2019 may limit NovaDel’s ability to market~~ its ~~oral~~financial ~~spray~~results ~~formulation~~ for EDthe inquarter ~~the~~ended ~~United~~September ~~States~~30, ~~("U~~2011.~~S.").~~ ~~The~~A ~~recent~~copy ~~court~~of ~~action~~the ~~does~~press ~~not~~release ~~limit~~is ~~its~~furnished ~~ability~~pursuant to ~~market~~this ~~its~~Item ~~formulation~~2.02 ~~outside~~as ~~the~~Exhibit U99.S.1 ~~after~~to ~~similar~~this ~~sildenafil~~Current ~~patents~~Report ~~expire~~on inForm ~~2013~~8-K.

~~Sildenafil~~This ~~citrate~~Current ~~has~~Report ~~two~~on ~~distinct~~Form ~~clinical~~8-K, ~~uses~~as it relates to Item 2.02, Inis ~~the~~being ~~decision~~furnished pursuant to ~~move~~Item ~~forward~~2.02 ~~with~~and the EDpress ~~application~~release is being furnished pursuant to Item 9.01 of ~~the~~this ~~compound,~~Current ~~NovaDel~~Report ~~considered~~on ~~its~~Form ~~alternative~~8-K ~~use~~and shall not be deemed “filed” for ~~chronic~~purposes ~~use~~of inSection ~~Pulmonary~~18 ~~Arterial~~of ~~Hypertension~~the Securities Exchange Act of 1934, as amended (~~"PAH"~~the “Exchange Act”)., ~~With~~or otherwise subject to the ~~recent~~liabilities ~~U.S.~~of ~~court~~that ~~decision~~Section, ~~NovaDel~~nor isshall ~~actively~~it ~~examining~~be ~~the~~deemed ~~opportunity~~incorporated toby ~~bring~~reference ~~its~~in ~~oral~~any ~~spray~~filing ~~formulation~~under tothe ~~this~~Securities ~~clinical~~Act ~~application~~of 1933, as amended, or the Exchange Act.

Given the clinical work performed to date, NovaDel believes it can add PAH to its program in a manner that, if funded, can bring a clinical advantage to patients suffering from this very debilitating disorder.

Item 9.01	Financial Statements and Exhibits.

	(d)	Exhibits

	Exhibit No.	Description

	99.1	Press Release of NovaDel Pharma Inc. dated November 1, 2011, titled “NovaDel Reports Financial Results for Third Quarter 2011.”

It should also be noted that in addition to seeking funding to pursue its company objectives, NovaDel is also examining a variety of strategic alternatives that would allow the Company to continue to develop its product portfolio.

The full text of the press release is set forth in Exhibit 99.1 hereto and incorporated herein.

Item 9.01	Financial Statements and Exhibits.
	(d)	Exhibits
	Exhibit No.	Description
	99.1	Press Release of NovaDel Pharma Inc. dated August 30, 2011, titled “Recent Events.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovaDel Pharma Inc. By: /s/ ~~Steven~~STEVEN B. ~~Ratoff~~RATOFF Name: Steven B. Ratoff Title: President, Chief Executive Officer and Interim Chief Financial Officer

Date: November ~~August 31~~1, 2011

Filing Compare · NOVADEL PHARMA INC